SCHEMBL3004366

SCHEMBL3004366

COc1ccc(S(=O)(=O)N2CCN(c3nc(-c4ccc(Cl)cc4Cl)cs3)CC2)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 2/20 0.53
MAPT P10636 6/20 0.49
RECQL P46063 2/20 0.49
USP2 O75604 1/20 0.49
HSD17B10 Q99714 1/20 0.49
POLB P06746 2/20 0.45
REV1 Q9UBZ9 1/20 0.45
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 4/20 0.43
LMNA P02545 3/20 0.43
MEN1 O00255 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
GAA P10253 1/20 0.43
MAPK1 P28482 1/20 0.43
TSHR P16473 1/20 0.43
ACLY P53396 1/20 0.43
KDM4E B2RXH2 2/20 0.42
HPGD P15428 1/20 0.42
RAB9A P51151 1/20 0.42
TP53 P04637 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3014719 0.93 AR (0.53) ARMAPTRECQLUSP2HSD17B10
SCHEMBL3017059 0.93 MAPT (0.49) ARMAPTRECQLUSP2HSD17B10
SCHEMBL3651521 0.92 KMT2A (0.50) ARMAPTRECQLUSP2HSD17B10
SCHEMBL3011444 0.91 MAPT (0.53) ARMAPTRECQLUSP2HSD17B10
SCHEMBL3019105 0.89 ALDH1A1 (0.52) ARMAPTRECQLUSP2HSD17B10
SCHEMBL3013792 0.89 MAPT (0.49) ARMAPTRECQLUSP2HSD17B10
SCHEMBL3016814 0.89 REV1 (0.53) ARMAPTRECQLUSP2HSD17B10
SCHEMBL3007441 0.89 MAPT (0.54) MAPTRECQLUSP2HSD17B10POLB
SCHEMBL3002440 0.89 AR (0.56) ARMAPTRECQLUSP2HSD17B10
SCHEMBL3010407 0.88 REV1 (0.57) ARMAPTRECQLUSP2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2188272-B1 PHENYL- AND BENZYLTHIAZOLYLPIPERAZINE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES REMYND NV (BE) 2016-02-24 EP disclosed
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA AR 3801/4885MAPT 18/4885RECQL 1564/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.